Organogenesis restructuring
This article was originally published in The Gray Sheet
Executive Summary
Skin substitute manufacturer is seeking licensing partners to fund development of coronary vascular graft, liver assist and pancreatic islet cell transplantation technologies, the firm says. Cost containment measures announced Feb. 25 are expected to save about $5 mil. this year and include a 16% workforce reduction as the company refocuses on its core bioengineered surgical products and living skin substitutes...